Trial · NCT01832532
A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
NCT01832532, Phase 1, Phase 2, Completed, Children's Hospital Medical Center, Cincinnati; results first posted 2020-10-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks. Trials, record NCT01832532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01832532
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
- NCT number
- NCT01832532
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Conditions
- Sleep Apnea, Sleep Disordered Breathing
- Interventions
- liraglutide
- First posted
- 2013-04-16
- Last updated
- 2020-10-20
- Results first posted
- 2020-10-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Apnea Hypopnea Index (AHI) From Baseline | Baseline and 4 weeks | Change in the number of apneas plus hypopnea events per hour of sleep from baseline at end of study. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Apnea Hypopnea Index (AHI) From Baseline | Baseline and 4 weeks | apnea / hypopnea events per hour sleep | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Apnea Hypopnea Index (AHI) From Baseline | Treatment Group- Liraglutide | 38.2 | Standard Deviation 30 | apnea / hypopnea events per hour sleep | |
| Change in Apnea Hypopnea Index (AHI) From Baseline | Control Group | 34 | Standard Deviation 20 | apnea / hypopnea events per hour sleep |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Group- Liraglutide | 23 | |
| Overall Study | STARTED | Control Group | 11 | |
| Overall Study | COMPLETED | Treatment Group- Liraglutide | 18 | |
| Overall Study | COMPLETED | Control Group | 9 | |
| Overall Study | NOT COMPLETED | Treatment Group- Liraglutide | 5 | |
| Overall Study | NOT COMPLETED | Control Group | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Group- Liraglutide | 0 | 18 |
| Total, all-cause mortality | Control Group | 0 | 9 |
| Total, other adverse events | Treatment Group- Liraglutide | 0 | 18 |
| Total, other adverse events | Control Group | 0 | 9 |
| Total, serious adverse events | Treatment Group- Liraglutide | 0 | 18 |
| Total, serious adverse events | Control Group | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1RR026314 | Cincinnati Center for Clinical and Translational Sciences and Training | HEUBI, JAMES E. | UNIVERSITY OF CINCINNATI | NATIONAL CENTER FOR RESEARCH RESOURCES | 2009 to 2011 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Treatment Group- Liraglutide vs Control Group: deaths from any cause | Trial comparisons |
| Treatment Group- Liraglutide vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01832532
GET https://conductscience.org/api/trials/v1/NCT01832532/registered